Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Aktis Oncology, Inc. (NASDAQ: AKTS)
AKTS Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-34.50%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
61.10%
AKTS Stock Analysis
AKTS
PE Ratio:
AKTS
PEG Ratio:
Not Available
AKTS
Forward EPS Growth (12 month):
0.00%
AKTS
PS Ratio:
159.2
AKTS
PSG Ratio:
-14.9
AKTS
Forward Revenue Growth (12 month):
-10.70%
AKTS Articles
No data was found